The Alcyone MEMS Cannula (AMC) provides for precise convection-enhanced CNS delivery directly to a neurological target.
15µ/min: Localized infusion in AMC, Severe loss of infusate in SC up to brain surface
|Anatomy||Max Flowrate(µL/min)||Backflow Prevented||MR Image Showing Gd Distribution|
|Attribute||Alcyone MEMS Cannula||Stepped Cannula|
|Minimum backflow at high flowrates|
|Repeatable infusate distributions|
|Target small anatomies with precision|
|Sensor capable platform|
Leveraging its dual channel tip for staggered delivery of AAV & gadolinium, successful delivery can be verified under MR.
Gadolinium is pushed out as AAV is infused from a second channel. Eventually, all the gadolinium is flushed out and a ring can be seen.
*The Alcyone MEMS Cannula (AMC™) System, a neuro-ventricular cannula, has US Food and Drug Administration (FDA) 510(k) clearance, Health Canada Licensing, and CE Marking. It is indicated for use in the U.S. and Canada for the injection of Cytarabine or the removal of cerebrospinal fluid from the ventricles of the brain during an intracranial procedure, and approved in Europe for injection or removal of substances from the brain and/or ventricles of the brain during intracranial procedures. The AMC is a dual-lumen, MR-compatible injection and aspiration cannula and can be used with existing commercial imaging and stereotactic systems. The AMC is not intended for implant, and it is intended for single patient use only.